Copyright © 1998 by the European Society of Cardiology.
Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison
accepted October 30, 1997Background
Angiotensin converting-enzyme (ACE) inhibitors used for the treatment of heart failure relieve symptoms, increase exercise performance, reduce hospital admissions and prolong life. The large survival studies have used higher doses of ACE inhibitors than those commonly used in clinical practice. NETWORK was set up to compare the effect of dose on the clinical outcome of ACE inhibition.
Methods and patients
1532 patients with heart failure drawn from primary care (n=619) and hospital sources (n=913) were randomized to receive enalapril 2·5mg twice daily (n=506), 5mg twice daily (n=510) or 10mg twice daily (n=516). The mean age was 70 years and 65% were male. Coronary heart disease was the cause of heart failure in 71%. Sixty-five percent were in NYHA class II and 35% in class III or IV. The mean left ventricular end-diastolic diameter was 59 (SD11)mm. The incidence of the primary end-point of death, heart failure related hospitalization or worsening heart failure was assessed after follow-up of each patient for 24 weeks.
Findings
The number of patients reaching the primary end-point was 62 (12·3%) in the 2·5mg twice daily group, 66 (12·9%) in the 5mg twice daily group and 76 (14·7%) in the 10mg twice daily group. Deaths in each group were 21 (4·2%), 17 (3·3%) and 15 (2·9%), respectively. There were no significant differences in the results between the three groups. The crude relative risk for the combined end-point in the 10mg twice daily group compared to the 2·5mg twice daily group was 1·20 (95% CI 0·88 to 1·64).
Interpretation
NETWORK did not demonstrate a relationship between dose of enalapril and clinical outcome in patients with heart failure selected from both primary care and hospital practice.
Key Words: ACE inhibition • heart failure • trial • dose • enalapril
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
 |
|
 2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 F.D.R. Hobbs Clinical burden and health service challenges of chronic heart failure Eur J Heart Fail Suppl, April 1, 2009; 8(suppl_1): i1 - i4. [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Hawkins, M. C. Petrie, P. S. Jhund, G. W. Chalmers, F. G. Dunn, and J. J.V. McMurray Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology Eur J Heart Fail, February 1, 2009; 11(2): 130 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Lenzen, E. Boersma, W. J.M. Scholte op Reimer, A. H.M.M. Balk, M. Komajda, K. Swedberg, F. Follath, M. Jimenez-Navarro, M. L. Simoons, and J. G.F. Cleland Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure Eur. Heart J., December 2, 2005; 26(24): 2706 - 2713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure Mayo Clin. Proc., December 1, 2005; 80(12): 1623 - 1630. [Abstract] [PDF]
|
|
|
|
|
|
F.D. R. Hobbs, J. Korewicki, J. G.F. Cleland, J. Eastaugh, N. Freemantle, and on behalf of the IMPROVEMENT Investigators The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice Eur J Heart Fail, August 1, 2005; 7(5): 768 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fonseca, T. Mota, H. Morais, F. Matias, C. Costa, A. G. Oliveira, F. Ceia, and on behalf of the EPICA Investigators The value of the electrocardiogram and chest X-ray for confirming or refuting a suspected diagnosis of heart failure in the community Eur J Heart Fail, October 1, 2004; 6(6): 807 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendon, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology Eur. Heart J., August 2, 2004; 25(16): 1454 - 1470. [Full Text] [PDF]
|
|
|
|
 |
|
 F D R Hobbs, R C Davis, A K Roalfe, R Hare, and M K Davies Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations Heart, August 1, 2004; 90(8): 866 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Roffman High-Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure Ann. Pharmacother., May 1, 2004; 38(5): 831 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Manyemba, A. A. Mangoni, K. W. Pettingale, and S. H.D. Jackson Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure Eur J Heart Fail, October 1, 2003; 5(5): 693 - 696. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]
|
|
|
|
|
|
F D R Hobbs Unmet need for diagnosis of heart failure: the view from primary care Heart, October 1, 2002; 88(90002): ii9 - 11. [Full Text] [PDF]
|
|
|
|
|
|
G.A. Cooke, S.G. Williams, P. Marshall, J.K. Al-Timman, J. Shelbourne, D.J. Wright, and L.-B. Tan A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients Eur. Heart J., September 1, 2002; 23(17): 1360 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ferrara, F Mastrorilli, G Pasanisi, S Censi, N D'aiello, A Fucili, M Valgimigli, and R Ferrari Neurohormonal modulation in chronic heart failure Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D3 - D11. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Nohria, E. Lewis, and L. W. Stevenson Medical Management of Advanced Heart Failure JAMA, February 6, 2002; 287(5): 628 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Wilson Tang, R. H. Vagelos, Y.-G. Yee, C. R. Benedict, K. Willson, C. L. Liss, P. LaBelle, and M. B. Fowler Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure J. Am. Coll. Cardiol., January 2, 2002; 39(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E Berezin Losartan in the Therapy of Heart Failure Patients Asian Cardiovasc Thorac Ann, December 1, 2001; 9(4): 302 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R McMullan and B Silke A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure Postgrad. Med. J., December 1, 2001; 77(914): 765 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bellotti, L.P. Badano, N. Acquarone, R. Griffo, G. Lo Pinto, A.P. Maggioni, C. Mattiauda, G. Menardo, and P. Mombelloni Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR study Eur. Heart J., April 1, 2001; 22(7): 596 - 604. [Abstract] [PDF]
|
|
|
|
|
|
J. N. Nanas, G. Alexopoulos, M. I. Anastasiou-Nana, K. Karidis, A. Tirologos, S. Zobolos, V. Pirgakis, L. Anthopoulos, D. Sideris, S. F. Stamatelopoulos, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Delahaye and G. de Gevigney Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established? J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2096 - 2097. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G F Cleland, A. Clark, and J. L Caplin Taking heart failure seriously BMJ, November 4, 2000; 321(7269): 1095 - 1096. [Full Text]
|
|
|
|
|
|
J. Mason, P. Young, N. Freemantle, and R. Hobbs Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction BMJ, November 4, 2000; 321(7269): 1113 - 1116. [Abstract] [Full Text]
|
|
|
|
|
|
F.D.R Hobbs, M.I Jones, T.F Allan, S Wilson, and R Tobias European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF) Eur. Heart J., November 2, 2000; 21(22): 1877 - 1887. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Lonn High dose lisinopril was more effective than low dose for reducing combined mortality and cardiovascular events in congestive heart failure Evid. Based Med., July 1, 2000; 5(4): 110 - 110. [Full Text]
|
|
|
|
|
|
H. M. Krumholz, D. W. Baker, C. M. Ashton, S. B. Dunbar, G. C. Friesinger, E. P. Havranek, M. A. Hlatky, M. Konstam, D. L. Ordin, I. L. Pina, et al. Evaluating Quality of Care for Patients With Heart Failure Circulation, March 28, 2000; 101 (12): e122 - e140. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gambassi, K. L. Lapane, A. Sgadari, P. Carbonin, C. Gatsonis, L. A. Lipsitz, V. Mor, R. Bernabei, and for the SAGE Study Group Effects of Angiotensin-Converting Enzyme Inhibitors and Digoxin on Health Outcomes of Very Old Patients With Heart Failure Arch Intern Med, January 10, 2000; 160(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Packer, P. A. Poole-Wilson, P. W. Armstrong, J. G. F. Cleland, J. D. Horowitz, B. M. Massie, L. Ryden, K. Thygesen, and B. F. Uretsky Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure Circulation, December 7, 1999; 100(23): 2312 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.J. van Veldhuisen, A. Charlesworth, H.J.G.M. Crijns, K.I. Lie, and J.R. Hampton Differences in drug treatment of chronic heart failure between European countries Eur. Heart J., May 1, 1999; 20(9): 666 - 672. [Abstract] [PDF]
|
|
|
|
|
|
H. P. Brunner-La Rocca, G. Vaddadi, and M. D. Esler Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. van Veldhuisen, S. Genth-Zotz, J. Brouwer, F. Boomsma, T. Netzer, A. J. Man in 't Veld, Y. M. Pinto, K. I. Lie, and H. J. G. M. Crijns High- versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1811 - 1818. [Abstract] [Full Text] [PDF]
|
|